You have read all your free articles, to continue reading subscribe to read the rest of this content.
Pelago Bioscience has been awarded a 3.6M SEK Swelife grant to use its patented CETSAâ technique to identify new oncology biomarkers to aid the treatment of childhood leukaemia. Pelago’s CETSA MS format can be used to profile the effect of a drug on up to 6000 proteins. This will be…
The Board of Directors of Oasmia has resolved on a new issue of shares with preferential rights for existing shareholders of approximately SEK 151 million. The purpose of the Rights Issue is to finance the continued development of the company and its projects in accordance with its business plan Already…
Orion’s collaboration partner Bayer has announced the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for the oral androgen receptor inhibitor (ARi) darolutamide in combination with docetaxel for the treatment of metastatiAlready a subscriber Login You have read all your…
The two companies can once again expand the Clinical Trials section of the U.S. label of their antidepressant Trintellix (vortioxetine) as the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application for the medicine. Trintellix is a prescription medicine approved Already a subscriber Login You have…
